May 18, 2024

Intravenous (IV) Ibuprofen Market is Estimated to Witness High Growth Owing to Increasing Adoption of Alternatives to Opioids

Intravenous (IV) ibuprofen belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is used for the treatment of pain, fever, and inflammation. It works by blocking the activity of an enzyme called cyclooxygenase (COX), which is involved in prostaglandin production and the inflammatory response. IV ibuprofen offers advantages over oral ibuprofen, such as predictable absorption and rapid onset of action. It is used to treat acute pain in adults, especially postsurgical pain and orthopedic pain. IV ibuprofen provides an alternative to opioids for postsurgical pain management.

The Global Intravenous (IV) Ibuprofen Market is estimated to be valued at US$ 11.13 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the Intravenous (IV) Ibuprofen are Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, Hikma Pharmaceuticals PLC.
The key opportunities in the market include newly approved products and upcoming pipeline products. There is a significant clinical need for non-opioid options to manage postsurgical pain.
Technological advancements include the development of formulations offering improved bioavailability and targeted delivery to optimize efficacy and safety profile. Novel formulations such as liposomal encapsulation and polymeric nanoparticles are being explored.

Market drivers
The primary drivers for growth of the Intravenous (IV) Ibuprofen Market Size are rising rates of surgeries and trauma coupled with the growing opioid epidemic. There is increasing preference among physicians and patients to limit the use of opioids for postsurgical pain management due to the risk of addiction and abuse. IV ibuprofen represents a safer, non-opioid alternative for postsurgical pain control and is also indicated for conditions like musculoskeletal injuries. Rising healthcare expenditure and availability of reimbursements further support the increased adoption of innovative therapeutics like IV ibuprofen formulations.
Current challenges in the Intravenous (IV) Ibuprofen market:

The intravenous ibuprofen market is currently facing several challenges. One of the major challenges is the presence of generic competition for oral ibuprofen. Since oral forms have been available generically for long, they pose pricing pressure on the intravenous forms. Furthermore, the need for hospital administration and healthcare professional supervision for intravenous administration makes it a more complex treatment method compared to oral drugs. This acts as a treatment barrier in certain cases. Similarly, lack of clinical evidence for some indications remains a challenge.

SWOT Analysis

Strength: Rapid pain relief through direct entry into bloodstream; suitable for patients who cannot take oral medications due to nausea, vomiting or other issues.
Weakness: Require administration by trained healthcare professionals in hospitals or clinics; higher costs involved than oral drugs.
Opportunity: Potential for treating more acute and post-surgical pain conditions; scope for iv formulation in pediatric patient population.
Threats: Strong competition from generic oral NSAIDs and other parenteral analgesics; regulatory issues regarding new indications and markets.

Geographical regions of concentration

North America currently accounts for the largest share in the intravenous ibuprofen market in terms of value. This is primarily due to favourable reimbursement policies and high healthcare spending in the region, as well as established clinical use. The United States represents a major chunk of the North American market.

Fastest growing region

The Asia Pacific region is expected to witness the fastest growth in the intravenous ibuprofen market during the forecast period. This is due to increasing healthcare investments, rising medical tourism, increasing incidences of chronic diseases and trauma/accident cases, expanding health insurance coverage and improving access to specialty care in emerging countries such as China and India.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it